<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225664</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0226</org_study_id>
    <secondary_id>NCI-2018-01107</secondary_id>
    <secondary_id>2017-0226</secondary_id>
    <secondary_id>R01CA155196</secondary_id>
    <nct_id>NCT03225664</nct_id>
  </id_info>
  <brief_title>Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced</brief_title>
  <official_title>A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trial studies the side effects and best dose of trametinib when given&#xD;
      together with pembrolizumab and to see how well they work in treating patients with non-small&#xD;
      cell lung cancer that has come back and spread to other places in the body, cannot be removed&#xD;
      by surgery, or spread to nearby tissues or lymph nodes. Trametinib may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with&#xD;
      monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the&#xD;
      cancer, and may interfere with the ability of tumor cells to grow and spread. Giving&#xD;
      trametinib and pembrolizumab may work better in treating patients with non-small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the toxicity profile of trametinib, a MEK inhibitor, in combination with&#xD;
      pembrolizumab, an anti PD-1 monoclonal antibody, as treatment for refractory to chemotherapy&#xD;
      KRAS mutation positive (mut+) and KRAS wild-type patients with advanced non-small cell lung&#xD;
      cancer (NSCLC) and establish a recommended dose for the combination for the phase II portion&#xD;
      of the study. (Part 1) II. To determine the 6-month overall response rate (ORR) for the&#xD;
      combination of trametinib + pembrolizumab in subjects with NSCLC who received prior cytotoxic&#xD;
      chemotherapy and anti-PD1 or anti-PD-L1 therapy. (Part 2)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate overall response rates (ORRs) using modified Response Evaluation Criteria in&#xD;
      Solid Tumors (RECIST 1.1 and immune related [ir]RECIST) and duration of response (DOR),&#xD;
      median progression free survival (PFS) and overall survival (OS) in KRAS mut+, KRAS&#xD;
      wild-type, PD-L1+ and PD-L1 negative cohorts of patients.&#xD;
&#xD;
      II. To evaluate ORRs by immune-related RECIST (irRECIST). III. To assess the safety and&#xD;
      tolerability of pembrolizumab in combination with trametinib at the recommended dose to be&#xD;
      used in future studies.&#xD;
&#xD;
      IV. To characterize the pharmacokinetics of trametinib and pembrolizumab when administered in&#xD;
      combination.&#xD;
&#xD;
      V. To identify prognostic and predictive markers for the two treatment regimens by analyzing&#xD;
      pre- and on-treatment tumor biopsies.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate exploratory genomic and gene expression biomarkers and their relationships in&#xD;
      tumors in response to study treatment.&#xD;
&#xD;
      II. Analyze circulating soluble factors including cytokines, chemokines, and antibodies&#xD;
      against tumor and self antigens in response to clinical outcomes.&#xD;
&#xD;
      III. Assess the activation state, quantity, and phenotype of T cells, B cells, and natural&#xD;
      killer cells and the presence of immune regulatory cells (myeloid-derived suppressor cells)&#xD;
      (MDSC) in response to treatment.&#xD;
&#xD;
      IV. Examine changes in the localization and numbers of tumor infiltrating lymphocytes (TILs)&#xD;
      expressing key markers (PD-1, CD8, CD4, CD45RO, granzyme, CD68, Foxp3) by&#xD;
      immunohistochemistry in response to treatment.&#xD;
&#xD;
      V. Perform immune monitoring studies in tissue and blood and correlate with genomic profiling&#xD;
      and outcomes including toxicities.&#xD;
&#xD;
      VI. Evaluate KRAS-mutation specific T cell response in patients before and after monotherapy&#xD;
      with PEMBROLIZUMAB and the combination of PEMBROLIZUMAB and trametinib.&#xD;
&#xD;
      VII. Evaluate immunophenotypes within the context of subsets of KRAS co-mutations (KRAS/p53,&#xD;
      KRAS/LKB1, KRAS/CDKN2A/B inactivation).&#xD;
&#xD;
      VIII. Collect and store archival diagnostic tumor samples, matched pre- and post-treatment&#xD;
      tumor biopsy samples and deoxyribonucleic acid (DNA) (from tumor and blood) for future&#xD;
      exploratory research into genes/genetic variation and factors that may influence resistance&#xD;
      and/or sensitivity, and/or response to trametinib and/or PEMBROLIZUMAB.&#xD;
&#xD;
      IX. Explore the relationship between pharmacokinetic (PK) plasma trametinib levels,&#xD;
      trametinib exposure, safety and clinical outcome measures.&#xD;
&#xD;
      X. Isolate peripheral blood mononuclear cells (PBMCs) from whole blood to enable flow&#xD;
      cytometric analysis of additional markers and perform functional testing for antigen&#xD;
      specificity and responsiveness, and T cell receptor (TCR) diversity.&#xD;
&#xD;
      XI. Perform flow cytometric analyses in tumor tissue. XII. Analysis of the host microbiome&#xD;
      from stool. XIII. Analysis of micro ribonucleic acid (miRNA) platelets and analysis in&#xD;
      response to study treatment.&#xD;
&#xD;
      OUTLINE: This is a phase Ib, dose-escalation study of trametinib followed by a phase II&#xD;
      study.&#xD;
&#xD;
      Patients receive trametinib orally (PO) once daily (QD) 14 days prior to cycle 1 and days&#xD;
      1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also&#xD;
      receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 3&#xD;
      weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and every 3 months&#xD;
      for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall objective response rate evaluated according to modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1 and immune related [ir]RECIST)</measure>
    <time_frame>At 6 months</time_frame>
    <description>Each patient will have the KRAS mutation and PD-L1 status determined prior to treatment in order for stratified randomization. A futility monitoring will be carried out continuously to each stratum within each treatment arm after the primary endpoints of 6 patients have been observed in the corresponding marker groups.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Metastatic Lung Non-Small Cell Carcinoma</condition>
  <condition>Recurrent Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <condition>Stage IIIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIIB Lung Cancer AJCC v8</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <condition>Unresectable Lung Non-Small Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (trametinib, pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (trametinib, pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (trametinib, pembrolizumab)</arm_group_label>
    <other_name>PHARMACOKINETIC</other_name>
    <other_name>PK Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (trametinib, pembrolizumab)</arm_group_label>
    <other_name>GSK1120212</other_name>
    <other_name>JTP-74057</other_name>
    <other_name>MEK Inhibitor GSK1120212</other_name>
    <other_name>Mekinist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of metastatic or unresectable,&#xD;
             locally advanced, recurrent NSCLC that has been previously treated (subjects who have&#xD;
             failed adjuvant or locally advanced therapy within 6 months are also eligible to&#xD;
             participate in the study)&#xD;
&#xD;
          -  The subject has biopsy accessible tumor and is willing to undergo biopsy prior to&#xD;
             planned protocol treatment&#xD;
&#xD;
          -  Confirmation of the presence or absence of EGFR mutations and ALK gene fusions prior&#xD;
             to study enrollment in all subjects except for patients with histologies other than&#xD;
             adenocarcinoma and NSCLC, not otherwise specified (NOS), as the frequency of these&#xD;
             alterations is exceedingly rare in this histology. Subjects with known EGFR&#xD;
             sensitizing mutational status or ALK fusion must have been treated and progressed on&#xD;
             EGFR TKIs or ALK-directed therapy, or with tumors harboring EGFR T790M mutation to&#xD;
             have received and progressed on therapy directed at the T790M mutation (e.g.&#xD;
             osimertinib). Subjects with known ROS1 translocation must have been treated and&#xD;
             progressed on ROS1-directed therapy&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 and irRECIST. At least one lesion of at&#xD;
             least 1.0 cm in the long-axis diameter for a non-lymph node or at least 1.5 cm in the&#xD;
             short-axis diameter for a lymph node which is serially measurable according to RECIST&#xD;
             1.1 and irRECIST using either computed tomography (CT) or magnetic resonance imaging&#xD;
             (MRI). If there is only one target lesion and it is a non-lymph node, it should have a&#xD;
             longest diameter of at least 1.5 cm&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L or at least 1500/mm^3 or at least 1.5&#xD;
             x 10^9/L&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 or at least 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions,&#xD;
             hematopoietic growth factors and hematinics are not allowed during the 7 days prior to&#xD;
             screening to correct Hb values less than 9 g/dL)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN) or &gt;= 60 mL/minute for subjects&#xD;
             with creatinine levels &gt; 1.5 x the institutional ULN&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 x ULN or direct bilirubin =&lt; ULN for subjects with total&#xD;
             bilirubin levels &gt; 1.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN&#xD;
             except for subjects with liver metastases (mets) for whom ALT and AST should be =&lt; 5 x&#xD;
             ULN&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 x ULN unless&#xD;
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin&#xD;
             time (PTT) is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          -  Activated PTT (aPTT) =&lt; 1.5 x ULN unless subject is receiving anticoagulant therapy as&#xD;
             long as PT or PTT is within therapeutic range of intended use of anticoagulant&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required. Female and male subjects of childbearing potential must be willing&#xD;
             to use an adequate method of contraception for the course of the study through 120&#xD;
             days after the last dose of study medication. Note: abstinence is acceptable if this&#xD;
             is the usual lifestyle and preferred contraception for the subject&#xD;
&#xD;
          -  Voluntary agreement to provide written informed consent and the willingness and&#xD;
             ability to comply with all aspects of the protocol&#xD;
&#xD;
          -  Patients must be able to swallow and retain oral medication and must not have any&#xD;
             clinically significant gastrointestinal abnormalities that may alter absorption such&#xD;
             as malabsorption syndrome or major resection of the stomach or bowels&#xD;
&#xD;
          -  Prior MEK inhibitor therapy is allowed&#xD;
&#xD;
          -  Prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other&#xD;
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)&#xD;
             is required for phase 2 part of the study. Subjects must be resistant (at least stable&#xD;
             disease at 12 weeks of treatment with anti-PD1, anti-PD-L1 therapy) (cohort A) or&#xD;
             refractory (progression within 12 weeks of starting anti-PD1 therapy) (cohort B) to an&#xD;
             Food and Drug Administration (FDA) approved anti PD 1/PD L1 monoclonal antibody (mAb)&#xD;
             as either monotherapy or in combination with other approved checkpoint inhibitors or&#xD;
             other therapies according to their label, defined as (subjects must meet all of the&#xD;
             following criteria):&#xD;
&#xD;
               -  Have received at least 2 doses of anti PD 1/PD L1 mAb&#xD;
&#xD;
               -  Progressive disease after anti PD 1/PD L1 mAb defined according to RECIST 1.1&#xD;
&#xD;
               -  Have documented progressive disease (PD) within 12 weeks of the last dose of anti&#xD;
                  PD 1/PD L1 mAb. Patients who were re-treated with anti PD 1/PD L1 mAb and&#xD;
                  patients who were on maintenance with anti PD 1/PD L1 mAb will be allowed to&#xD;
                  enter the trial as long as there is documented PD within 12 weeks of the last&#xD;
                  treatment date (with anti PD 1/PD L1 mAb)&#xD;
&#xD;
                    -  Note - Subjects who have withdrawn from standard treatment due to&#xD;
                       unacceptable toxicity warranting discontinuation of that treatment and&#xD;
                       precluding retreatment with the same agent before progression of disease&#xD;
                       will also be eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects participating in or who have participated in a study of an investigational&#xD;
             agent or is using an investigational device within 4 weeks of the first dose of study&#xD;
             treatment or have received any anti-cancer therapy, platinum-based chemotherapy,&#xD;
             targeted, biological (including humanized antibodies), investigational, immunotherapy,&#xD;
             or hormonal agent, within 4 weeks of the first dose of study treatment&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment&#xD;
&#xD;
          -  Has had prior monoclonal antibody therapy within 4 weeks prior to study day 1 or who&#xD;
             has not recovered (i.e., =&lt; grade 1 or at baseline) from adverse events (AEs) due to&#xD;
             agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Has received previous treatment with an immunomodulatory therapy (eg, anti PD 1/PD L1&#xD;
             or CTLA-4 agent) and was discontinued from that therapy due to a grade 3 or higher&#xD;
             immune-related adverse event (irAE)&#xD;
&#xD;
          -  Had prior chemotherapy, targeted small molecule therapy within 4 weeks, or radiation&#xD;
             therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =&lt; grade 1&#xD;
             or at baseline) from AEs due to a previously administered agent&#xD;
&#xD;
               -  Note: subjects with =&lt; grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study&#xD;
&#xD;
               -  Note: if a subject received major surgery, they must have recovered adequately&#xD;
                  from the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy&#xD;
&#xD;
               -  Note: patients who have received &gt; 30 Gy to the thorax must have completed this&#xD;
                  radiation 6 months prior to enrollment in the study&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell and squamous cell carcinoma of the skin, or in situ&#xD;
             cervical cancer that has undergone potentially curative therapy&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             they are stable (without evidence of progression by imaging for at least 4 weeks prior&#xD;
             to the first dose of study treatment and any neurologic symptoms have returned to&#xD;
             baseline), have no evidence of new or enlarging brain metastases, and are not using&#xD;
             steroids for at least 7 days prior to study treatment&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment&#xD;
&#xD;
          -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis, or&#xD;
             has history of pneumonitis that required systemic corticosteroids for recovery&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has symptomatic ascites or pleural effusion. A subject who is clinically stable&#xD;
             following treatment for these conditions (including therapeutic thoraco- or&#xD;
             paracentesis) is eligible&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the study, or in the opinion of the&#xD;
             investigator, is not in the best interest of the subject to participate&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that could interfere with&#xD;
             cooperation with the requirements of the protocol&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to become pregnant or father a child within&#xD;
             the projected duration of the study, starting with the pre-screening or screening&#xD;
             visit through 120 days after the last dose of study drug&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) (HIV Â½ antibodies)&#xD;
&#xD;
          -  Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or&#xD;
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative]) is&#xD;
             detected&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of study drug&#xD;
&#xD;
          -  History or current evidence/risk of retinal vein occlusion (RVO)&#xD;
&#xD;
          -  Patients who are currently receiving treatment with any medications that have the&#xD;
             potential to prolong the QT interval if that treatment cannot be either discontinued&#xD;
             or switched to a different medication (not known to affect QT interval) prior to cycle&#xD;
             1 day 1 (C1D1)&#xD;
&#xD;
          -  Any of the following cardiac abnormalities or history: a) clinically significant&#xD;
             abnormal 12-lead electrocardiogram (ECG), QT interval (QT corrected by Bazett's&#xD;
             formula [QTCB]) &gt; 480 ms, b) inability to measure QT interval on ECG, c) personal or&#xD;
             family history of long QT syndrome, d) implantable pacemaker or implantable&#xD;
             cardioverter defibrillator, e) resting bradycardia &lt; 55 beats/min, f) history or&#xD;
             evidence of current clinically significant uncontrolled arrhythmias. Exception:&#xD;
             subjects with controlled atrial fibrillation for &gt; 30 days prior to randomization are&#xD;
             eligible, g) history of acute coronary syndromes (including myocardial infarction and&#xD;
             unstable angina), coronary angioplasty, or stenting, within 6 months prior to&#xD;
             randomization, h) history or evidence of current &gt;= class II congestive heart failure&#xD;
             as defined by New York Heart Association (NYHA), i) treatment refractory hypertension&#xD;
             defined as a blood pressure of systolic &gt; 140 mm Hg and/or diastolic &gt; 90 mm Hg which&#xD;
             cannot be controlled by antihypertensive therapy, j) cardiac metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

